{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:38:13Z","timestamp":1788871093900,"version":"build-2803163510"},"reference-count":13,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T00:00:00Z","timestamp":1337212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Natural Key Basic Research and Development Program","award":["973 Program"],"award-info":[{"award-number":["973 Program"]}]},{"name":"Natural Key Basic Research and Development Program","award":["2011CB710800"],"award-info":[{"award-number":["2011CB710800"]}]},{"name":"National Major Special Project for Science and Technology Development of Ministry of Science and Technology of China","award":["2012ZX09506001-004"],"award-info":[{"award-number":["2012ZX09506001-004"]}]},{"name":"National Major Special Project for Science and Technology Development of Ministry of Science and Technology of China","award":["2009ZX09304-003"],"award-info":[{"award-number":["2009ZX09304-003"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chirality"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Besifloxacin hydrochloride is a novel chiral broad\u2010spectrum fluoroquinolone developed for the treatment of bacterial conjunctivitis.\n                    <jats:italic>R<\/jats:italic>\n                    \u2010besifloxacin hydrochloride is used in clinics as a consequence of its higher antibacterial activity. To establish an enantiomeric impurity determination method, some chiral stationary phases (CSPs) were screened. Besifloxacin enantiomers can be separated to a certain extent on Chiral CD\u2010Ph (Shiseido Co., Ltd., Japan), Chiral AGP, and Crownpak CR (+) (Daicel Chemical IND., Ltd., Japan). However, the selectivity and sensitivity were both unsatisfactory on these three CSPs. Therefore, Chiral AGP, Chiral CD\u2010Ph, and Crownpak CR (+) were not used in the enantiomeric impurity determination of besifloxacin hydrochloride. The separation of enantiomers of besifloxacin was further performed using a precolumn derivatization chiral high\u2010performance liquid chromatography method. 2,3,4,6\u2010Tetra\u2010O\u2010acetyl\u2010beta\u2010D\u2010glucopyranosyl isothiocyanate was used as the derivatization reagent. Besifloxacin enantiomer derivates were well separated on a C\n                    <jats:sub>18<\/jats:sub>\n                    column (250\u2009\u00d7\u20094.6\u2009mm, 5\u2009\u00b5m) with a mobile phase that consisted of methanol\u2010KH\n                    <jats:sub>2<\/jats:sub>\n                    PO\n                    <jats:sub>4<\/jats:sub>\n                    buffer solution (20\u2009mM; pH\u20093.0) (50:50, v\/v). Selectivity, sensitivity, linearity, accuracy, precision, stability, and robustness of this method were all satisfied with the method validation requirement. The method was suitable for the quality control of enantiomeric impurity in besifloxacin hydrochloride.\n                    <jats:italic>Chirality 24:526\u2013531, 2012<\/jats:italic>\n                    . \u00a9 2012 Wiley Periodicals, Inc.\n                  <\/jats:p>","DOI":"10.1002\/chir.22042","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T13:46:59Z","timestamp":1337262419000},"page":"526-531","source":"Crossref","is-referenced-by-count":22,"title":["Determination of enantiomeric impurity in besifloxacin hydrochloride by chiral high\u2010performance liquid chromatography with precolumn derivatization"],"prefix":"10.1002","volume":"24","author":[{"given":"Zhangting","family":"Wang","sequence":"first","affiliation":[{"name":"College of Pharmaceutical Sciences Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjia","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[{"name":"R&amp;D Center Jiangsu Yabang Pharmaceutical (group) Co., Ltd.  Jintan Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixin","family":"Chen","sequence":"additional","affiliation":[{"name":"R&amp;D Center Jiangsu Yabang Pharmaceutical (group) Co., Ltd.  Jintan Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lushan","family":"Yu","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Zeng","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.03.013"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S9604"},{"key":"e_1_2_6_4_1","volume-title":"FDA policy statement for the development of new stereoisomeric drugs","year":"1992"},{"key":"e_1_2_6_5_1","unstructured":"www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022308s000_MicroR.pdf.2009 p.24\u201326."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.164"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.200800610"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-022X(02)00117-3"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(88)80015-X"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02262467"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(00)00322-8"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02535722"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(99)00085-7"},{"key":"e_1_2_6_14_1","unstructured":"ICH.Guidance for industry Q2B validation of analytical procedures: methodology 1996."}],"container-title":["Chirality"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fchir.22042","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fchir.22042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/chir.22042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T12:45:01Z","timestamp":1698756301000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/chir.22042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1002\/chir.22042"],"URL":"https:\/\/doi.org\/10.1002\/chir.22042","archive":["Portico"],"relation":{},"ISSN":["0899-0042","1520-636X"],"issn-type":[{"value":"0899-0042","type":"print"},{"value":"1520-636X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]}}}